84 results
S-3ASR
AUTL
Autolus Therapeutics plc
28 Mar 24
Automatic shelf registration
4:10pm
no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. The selling securityholder … expressed or implied by our forward-looking statements. As a result of these factors, there can be no assurance that the forward-looking statements
10-K
2023 FY
EX-10.12
AUTL
Autolus Therapeutics plc
21 Mar 24
Annual report
4:55pm
and stability testing, assay development and audit development, toxicology, formulation, quality assurance/quality control development, technical development … , manufacturing, supplying, processing, compounding, filling, finishing, packing, packaging, labeling, leafleting, quality assurance, quality control testing
10-K
2023 FY
EX-31.1
AUTL
Autolus Therapeutics plc
21 Mar 24
Annual report
4:55pm
, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
10-K
2023 FY
EX-31.2
AUTL
Autolus Therapeutics plc
21 Mar 24
Annual report
4:55pm
, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
10-K
2023 FY
AUTL
Autolus Therapeutics plc
21 Mar 24
Annual report
4:55pm
this is a relatively new and expanding area of novel therapeutic interventions, there can be no assurance as to the length of the trial period, the number of patients … , proposed labeling and other relevant information. The testing and approval processes require substantial time and effort and there can be no assurance
424B5
999sjy7y9za21h4whb
9 Feb 24
Prospectus supplement for primary offering
5:15pm
8-K
EX-1.1
oak752t7mdy1bbnt6gc8
8 Feb 24
Autolus Announces Pricing of Underwritten Offering
4:17pm
8-K
EX-99.1
saprmeb91trhc40u9b
8 Feb 24
Autolus Announces Pricing of Underwritten Offering
4:17pm
8-K
EX-10.1
ar4iuhb
8 Feb 24
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
6:06am
S-3ASR
cxrrl
7 Feb 24
Automatic shelf registration
10:00pm
S-3ASR
EX-5.2
64f111sreov
7 Feb 24
Automatic shelf registration
10:00pm
10-Q
EX-31.1
ncki1g
9 Nov 23
Quarterly report
4:18pm
10-Q
h8h0rikf
9 Nov 23
Quarterly report
4:18pm
10-Q
EX-31.2
wom93nm3s7o7odvip6q
9 Nov 23
Quarterly report
4:18pm
6-K
EX-99.1
vqclj6r 8qcp2afu5k
9 Dec 22
Autolus Announces Pricing of Public Offering
5:43pm
6-K
EX-1.1
r4by d4udto7vf2dc7ow
9 Dec 22
Autolus Announces Pricing of Public Offering
5:43pm
424B5
wga5msm31c
9 Dec 22
Prospectus supplement for primary offering
5:40pm
6-K
EX-99.2
kefr5g0wc o7e3
8 Dec 22
Current report (foreign)
4:16pm
424B5
cc0u4ufp
8 Dec 22
Prospectus supplement for primary offering
4:10pm
6-K
EX-1
i7gs43h8qtci s0
1 Jul 22
Current report (foreign)
5:15pm